SCHEMBL5136205

SCHEMBL5136205

CCCCn1c(CN(CCc2ccccc2)Cc2ccc(C)cc2C)cnc1-c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.39
HSD11B1 P28845 2/20 0.38
GRIN1 Q05586 1/20 0.37
GRIN2B Q13224 1/20 0.37
C5AR1 P21730 1/20 0.35
DRD2 P14416 3/20 0.34
OPRM1 P35372 3/20 0.34
DRD3 P35462 3/20 0.34
OPRD1 P41143 3/20 0.34
OPRK1 P41145 3/20 0.34
USP2 O75604 2/20 0.34
ALDH1A1 P00352 2/20 0.34
MEN1 O00255 1/20 0.34
GAA P10253 1/20 0.34
MAPT P10636 1/20 0.34
KMT2A Q03164 1/20 0.34
CRHR1 P34998 3/20 0.33
KCNA5 P22460 1/20 0.33
KCNJ5 P48544 1/20 0.33
KCNJ3 P48549 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5137919 0.93 TSHR (0.39) TSHRHSD11B1C5AR1DRD2OPRM1
SCHEMBL5136207 0.91 TSHR (0.41) TSHRHSD11B1GRIN1GRIN2BC5AR1
SCHEMBL5137926 0.87 TSHR (0.41) TSHRHSD11B1C5AR1DRD2OPRM1
SCHEMBL5134920 0.87 HSD11B1 (0.44) TSHRHSD11B1C5AR1DRD2OPRM1
SCHEMBL5075074 0.87 TSHR (0.46) TSHRHSD11B1DRD2OPRM1DRD3
SCHEMBL5135195 0.86 TSHR (0.38) TSHRHSD11B1C5AR1DRD2OPRM1
SCHEMBL5135727 0.86 TSHR (0.39) TSHRHSD11B1C5AR1DRD2OPRM1
SCHEMBL5135358 0.85 HSD11B1 (0.42) TSHRHSD11B1C5AR1DRD2OPRM1
SCHEMBL5135197 0.85 TSHR (0.40) TSHRHSD11B1C5AR1DRD2OPRM1
SCHEMBL5135696 0.85 TSHR (0.40) TSHRHSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed